Angiogenic activity of fibrin degradation products is located in fibrin fragment E.
The source of angiogenic activity of fibrin degradation products has been sought in a series of experiments, applying degradation products from different types of fibrin and fibrinogen to the chick chorioallantoic membrane. The presence of platelets or fibronectin during clotting was not essential for activity, and neither was crosslinking. Fibrinogen degradation products were non-stimulatory, as was serum. Molecular sieve column chromatography indicated a range of active fragments. Admixture of active fibrin degradation products with antifibrin fragment E, but not D, antiserum neutralized activity. Preparations containing only fibrin fragment E retained activity. A commercial preparation of fibrinogen fragment E was inactive until treated with thrombin. These experiments point to fibrin fragment E being the source of angiogenic activity, with thrombin cleavage being the essential step in generating activity.
D000818:Animals; D002642:Chick Embryo; D004305:Dose-Response Relationship, Drug; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D015151:Immunoblotting; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D013917:Thrombin / Q000378:metabolism
D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; C018543:fibrinogen fragment E; D013917:Thrombin